Infant Bacterial Therapeutics announces FDA has granted Breakthrough Therapy designation for IBP-9414's potential to reduce gastrointestinal-related mortality (SEK 37.30, 0.00)
BioGaia releases sustainability report (SEK 109.00, -2.70)
BioGaia discloses Anatom Holding becomes anchor shareholder (SEK 116.50, 0.00)
Powered by FactSet Research Systems Inc.